Compare · NAVB vs NEOG
NAVB vs NEOG
Side-by-side comparison of Navidea Biopharmaceuticals Inc. (NAVB) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAVB and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $1.92B, about 63.8x NAVB ($30.1M).
- NEOG has hit the wire 2 times in the past 4 weeks while NAVB has been quiet.
- NEOG has more recent analyst coverage (5 ratings vs 0 for NAVB).
- Company
- Navidea Biopharmaceuticals Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- $30.1M
- $1.92B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- AMEX
- NASDAQ
- IPO
- 1989
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 5
Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest NAVB
- Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
- Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
- Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
- Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
- Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
- SEC Form SC 13D/A filed by Navidea Biopharmaceuticals Inc. (Amendment)
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
Latest NEOG
- SEC Form SD filed by Neogen Corporation
- Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares (SEC Form 4)
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neogen Reports Third Quarter Fiscal Year 2026 Financial Results